Healthcare Industry News: atorvastatin
News Release - January 14, 2008
Pfizer Receives Initial Communication from U.S. Patent and Trademark Office Regarding Lipitor Basic Patent
NEW YORK--(HSMN NewsFeed)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued its first communication in the reexamination of the ‘893 basic patent for Lipitor, initially rejecting the patent’s claims. This initial action, which is how the Office raises its issues with the patentee, will now be followed by the company’s response, in which Pfizer will address those issues raised by the examiner. As the company previously indicated, an initial rejection is not unusual in reexamination proceedings.“We will respond as appropriate to the issues raised by the examiner, and believe we have compelling arguments in our favor,” said Pfizer General Counsel Allen Waxman. “We continue to believe that the basic patent was properly granted and will be upheld on reexamination. This initial action, which was not unexpected, does not change that.”
The patent remains valid and enforceable throughout the re-examination proceeding, which could take as long as a few years.
More information can be found at www.pfizer.com.
Source: Pfizer
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!